8-K: Harrow Reaffirms 2025 Revenue, Appoints New CCO

Harrow, Inc. reaffirmed its full-year 2025 revenue guidance and announced the promotion of Patrick W. Sullivan to Chief Commercial Officer.

Summary

• Harrow, Inc. reaffirmed its full-year 2025 revenue guidance to be between $270 million and $280 million.
• Patrick W. Sullivan was appointed Chief Commercial Officer, effective January 30, 2026, bringing over 25 years of commercial leadership experience.
• The company is on track to double its VEVYE sales force from approximately 50 to 100 territories by Memorial Day 2026.
• Harrow is expanding the commercial footprint of IHEEZO to target the office-based setting, estimating over 2.5 million annual procedures.
• Plans are underway to double the surgical sales force supporting TRIESENCE in the coming months.
• The 'OneHarrow' initiative has been launched to unify branding and operations under a single Harrow brand for greater focus and efficiency.
• MELT-300 and MELT-210 programs are on track for New Drug Application (NDA) filings, with MELT-300 NDA submission targeted for the first half of 2027.
• Harrow's ImprimisRx division settled pending regulatory matters with the California Board of Pharmacy, agreeing to a $157,000 administrative fine and voluntarily exiting the California market effective February 1, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The reaffirmation of revenue guidance, strategic sales force expansions, and leadership strengthening are strong operational signals, partially offset by the regulatory fine and market exit in California, which is deemed not financially material.

Positives

• Reaffirmation of full-year 2025 revenue guidance of $270 million to $280 million indicates stable financial performance and management confidence.
• Strategic expansion plans for VEVYE, IHEEZO, and TRIESENCE sales forces are expected to fuel market share expansion and accelerate demand for key products.
• The 'OneHarrow' initiative aims to improve operational efficiency, alignment, and unified execution across the organization.
• The appointment of Patrick W. Sullivan as Chief Commercial Officer strengthens the leadership team with extensive commercial experience.
• MELT-300 and MELT-210 programs are progressing as planned towards New Drug Application (NDA) filings, indicating pipeline advancement.

Negatives

• ImprimisRx incurred an administrative fine of approximately $157,000 from the California Board of Pharmacy.
• ImprimisRx voluntarily exited the California market due to an increasingly unpredictable, costly, and punitive regulatory environment, ceasing service to California eyecare professionals and patients.

Risks

• Risks related to liquidity or results of operations.
• Ability to successfully implement the business plan, develop and commercialize products, and manage pharmacy operations.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks, including litigation matters, and uncertainties related to pharmacy operations.
• Physician interest in and market acceptance of current and future formulations and compounding pharmacies generally.

Future Outlook

Harrow anticipates another record-setting year of growth, driven by strategic sales force expansions for VEVYE, IHEEZO, and TRIESENCE, and the unifying 'OneHarrow' initiative. The company expects to file a New Drug Application for MELT-300 in the first half of 2027, indicating continued pipeline development.

Management Comments

• "Our team delivered another year of strong growth in 2025, supported by positive demand trends across our key revenue-driving products, as well as meaningful progress with other parts of our portfolio."
• "As we begin what we believe will be another record-setting year of growth, after many years operating under two separate commercial organizations (ImprimisRx and Harrow), the OneHarrow initiative will provide greater focus, tighter alignment, and a unified effort, driving disciplined and coordinated execution across a single organization."
• "We are also excited to expand IHEEZO's focus to a targeted, separately reimbursed office-based procedures market, which we estimate exceeds 2.5 million procedures annually."
• "I also want to congratulate Pat Sullivan on his promotion to Chief Commercial Officer. Over the past 5 months, he has stepped in and has improved the structure and focus of our commercial organization."
• "I especially appreciate that Pat enthusiastically agreed to his new equity incentives as performance stock units that vest upon achieving our company-wide revenue goal of $230 million in branded revenue in a calendar quarter. In this regard, he is 100% aligned with what we are working toward and committed to delivering for our stockholders."

Industry Context

StockSavvy.ai notes that Harrow's focus on expanding its ophthalmic product portfolio and sales reach aligns with broader trends in the specialized pharmaceutical market, where targeted commercial strategies are crucial for growth. The emphasis on office-based procedures for IHEEZO taps into a growing segment of ophthalmic care, potentially increasing market penetration. The consolidation under 'OneHarrow' reflects a common strategy among companies to streamline operations and enhance brand synergy in competitive markets.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Harrow's ImprimisRx division settled all pending regulatory matters with the California Board of Pharmacy, agreeing to an administrative fine of approximately $157,000.

Stakeholder Impact

• Shareholders: Reaffirmed revenue guidance provides stability, while strategic expansions and leadership changes aim for future growth. The California exit is stated as not financially material.
• Employees: Promotion of Patrick W. Sullivan and expansion of sales forces indicate growth and potential opportunities within the company.
• Customers (Eyecare Professionals and Patients): ImprimisRx's exit from California means compounded formulations will no longer be available from Harrow in that state, though branded products will continue to be served. Expanded sales forces and product focus aim to improve access and service in other markets.
• Regulatory Authorities: Settlement with the California Board of Pharmacy resolves past issues but highlights regulatory challenges in certain states.

Next Steps

• Double the VEVYE sales force from approximately 50 to 100 territories by Memorial Day 2026.
• Expand IHEEZO's commercial focus to the office-based setting.
• Double the surgical sales force supporting TRIESENCE in the coming months.
• Continue progress toward filing New Drug Applications for MELT-300 and MELT-210.
• Submit the NDA for MELT-300 in the first half of 2027.
• Release full-year 2025 financial results in early March 2026.

Key Dates

Recommendation

The reaffirmation of revenue guidance is a neutral signal, indicating performance is as expected. While strategic initiatives like sales force expansions and the 'OneHarrow' program are positive for long-term growth, they are not immediate catalysts for a 'buy' recommendation. The regulatory settlement and exit from California, though deemed not financially material, introduce a minor negative. A 'hold' recommendation reflects a stable outlook with ongoing strategic execution, but without significant new upside or downside information to warrant a change in position.

Keywords

Ophthalmic, Pharmaceuticals, Revenue Guidance, Chief Commercial Officer, Sales Force Expansion, VEVYE, IHEEZO, TRIESENCE, OneHarrow, NDA Filing, MELT-300, ImprimisRx, Regulatory Settlement, HROW